Canton Strategic (CNTN) vs Satellos Bioscience (MSLE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Satellos Bioscience (MSLE) has outperformed Canton Strategic (CNTN) over the past year, gaining 7.4% versus a loss of 34.6%. Canton Strategic is the larger company by market cap ($165.7 million vs $155.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CNTN | MSLE |
|---|---|---|
| Share price | $2.08 | $7.35 |
| Market cap | $165.74M | $155.83M |
| 1-day change | -7.96% | -3.74% |
| YTD return | -31.35% | +24.91% |
| 1-year return | -34.59% | +7.38% |
| 5-year return | — | -50.84% |
| EPS (TTM) | $-0.10 | $-1.95 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.89 | $13.40 |
| 52-week low | $1.75 | $5.30 |
| Distance from 52-week high | -69.81% | -45.17% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +251.26% |
| Average volume | 758.86K | 50.10K |
| Shares outstanding | 79.68M | 21.22M |
| Employees | 12 | 18 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MSLE has outperformed CNTN by 42.0 percentage points over the past year.
About Canton Strategic
CNTN stock →Canton Strategic Holdings, Inc. engages in the institutional blockchain adoption and digitization of financial markets in the United States.
Healthcare · Biotechnology · 12 employees
About Satellos Bioscience
MSLE stock →Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo.
Healthcare · Biotechnology · 18 employees
CNTN vs MSLE FAQ
Which is bigger, Canton Strategic or Satellos Bioscience?
Canton Strategic (CNTN) is larger, with a market capitalization of $165.74M compared with $155.83M for Satellos Bioscience (MSLE).
Which stock has performed better over the past year, CNTN or MSLE?
MSLE returned +7.38% over the past 12 months, compared with -34.59% for CNTN (price return, excluding dividends). Past performance does not predict future results.
Are Canton Strategic and Satellos Bioscience in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.